New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.

The researchers conducted a cohort study using data from more than 6 million adults from the Veterans Health Administration ...

While Medicare covers vaccines — including vaccines for the flu, pneumonia, hepatitis B and COVID-19 — under Part B (medical insurance) to treat exposure to a disease, Part D covers all vaccines to ...

Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST To access the live webcast of the fireside chat, please visit: ...

Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B ...

A study published in 2023 highlights significant discoveries that were only made possible through DNA analysis of Beethoven’s hair.

Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

Screening rates for hepatitis D virus are not ideal among individuals with hepatitis B virus, who also have a higher all-cause mortality rate.

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

Portal vein thrombosis (PVT) is a challenging complication in liver cirrhosis, with no currently available sensitive diagnostic markers.